Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Triple-negative breast cancer (TNBC) remains an aggressive disease without effective targeted therapies. In this study, we addressed this challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768 pairwise drug combinations in TNBC cell lines to identify synergistic combinations tractable to clinical translation. Medium-throughput results were scrutinized and extensively analyzed for sensitivity patterns, synergy, anticancer activity, and were validated in low-throughput experiments. Principal component analysis revealed that a fraction of all upregulated or downregulated genes of a particular targeted pathway could partly explain cell sensitivity toward agents targeting that pathway. Combination therapies deemed immediately tractable to translation included ABT-263/crizotinib, ABT-263/paclitaxel, paclitaxel/JQ1, ABT-263/XL-184, and paclitaxel/nutlin-3, all of which exhibited synergistic antiproliferative and apoptotic activity in multiple TNBC backgrounds. Mechanistic investigations of the ABT-263/crizotinib combination offering a potentially rapid path to clinic demonstrated RTK blockade, inhibition of mitogenic signaling, and proapoptotic signal induction in basal and mesenchymal stem-like TNBC. Our findings provide preclinical proof of concept for several combination treatments of TNBC, which offer near-term prospects for clinical translation. Cancer Res; 77(2); 566-78. ©2016 AACR.

[1]  A. Shamas-Din,et al.  A phase I study of elesclomol sodium in patients with acute myeloid leukemia , 2016, Leukemia & lymphoma.

[2]  Gary D Bader,et al.  Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance , 2016, Cell.

[3]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[4]  James E. Bradner,et al.  Response and resistance to BET bromodomain inhibitors in triple negative breast cancer , 2015, Nature.

[5]  Shaomeng Wang,et al.  SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells , 2015, Oncotarget.

[6]  J. V. van Meerbeeck,et al.  The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer , 2015, Oncotarget.

[7]  E. Olejniczak,et al.  Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer , 2015, Cell Death and Differentiation.

[8]  R. Mamillapalli,et al.  The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF‐mutant melanoma cells in combination with other signaling pathway inhibitors , 2015, Pigment cell & melanoma research.

[9]  J. Schiller,et al.  Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  Yi-Ren Hong,et al.  Combining Paclitaxel with ABT-263 Has a Synergistic Effect on Paclitaxel Resistant Prostate Cancer Cells , 2015, PloS one.

[11]  L. Ouyang,et al.  Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery , 2015, Oncotarget.

[12]  J. Kanwar,et al.  YM155 down‐regulates survivin and XIAP, modulates autophagy and induces autophagy‐dependent DNA damage in breast cancer cells , 2015, British journal of pharmacology.

[13]  J. Crown,et al.  Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[14]  D. Nguyen,et al.  Significance of glioma-associated oncogene homolog 1 (GLI1)expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway , 2014, Breast Cancer Research.

[15]  M. Duffy,et al.  cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? , 2014, Expert opinion on therapeutic targets.

[16]  Robert Clarke,et al.  Enhancing reproducibility in cancer drug screening: how do we move forward? , 2014, Cancer research.

[17]  K. Hess,et al.  Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab , 2014, Oncotarget.

[18]  V. Karantza,et al.  A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors , 2014, Investigational New Drugs.

[19]  Jinwon Seo,et al.  MET is a potential target for use in combination therapy with EGFR inhibition in triple‐negative/basal‐like breast cancer , 2014, International journal of cancer.

[20]  D. Lane,et al.  Drugging the p53 pathway: understanding the route to clinical efficacy , 2014, Nature Reviews Drug Discovery.

[21]  A. Errico.  CNS cancer: New options for glioblastoma , 2014, Nature Reviews Clinical Oncology.

[22]  A. Errico.  Screening: High-throughput screen identifies a roadmap for combination drug trials , 2014, Nature Reviews Clinical Oncology.

[23]  Qiang Zhang,et al.  Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. , 2014, Cancer cell.

[24]  Sam Michael,et al.  High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.

[25]  Suzanne F. Jones,et al.  A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors , 2013, Cancer Chemotherapy and Pharmacology.

[26]  Miles A. Miller,et al.  The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells , 2013, Science Signaling.

[27]  F. Cavalli,et al.  Differential expression of testin and survivin in breast cancer subtypes. , 2013, Oncology reports.

[28]  A. Hauschild,et al.  Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. O'toole,et al.  Therapeutic targets in triple negative breast cancer , 2013, Journal of Clinical Pathology.

[30]  A. Richardson,et al.  Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells. , 2013, Gynecologic oncology.

[31]  Peter J. Park,et al.  Systematic Identification of Synergistic Drug Pairs Targeting HIV , 2012, Nature Biotechnology.

[32]  Anastasia Ivanova,et al.  TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[34]  G. Giaccone,et al.  Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer , 2012, Clinical Cancer Research.

[35]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[36]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[37]  J. Scannell,et al.  Diagnosing the decline in pharmaceutical R&D efficiency , 2012, Nature Reviews Drug Discovery.

[38]  Christopher P. Austin,et al.  Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. , 2012, Cancer research.

[39]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[40]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[41]  C. Rudin,et al.  Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Zha,et al.  Navitoclax Enhances the Efficacy of Taxanes in Non–Small Cell Lung Cancer Models , 2011, Clinical Cancer Research.

[43]  E. Winer,et al.  Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer , 2010, Clinical Cancer Research.

[44]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[45]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  P. Sylvester,et al.  Synergistic Antiproliferative Effects of γ-Tocotrienol and Statin Treatment on Mammary Tumor Cells , 2007, Lipids.

[47]  P. Sorger,et al.  Systems biology and combination therapy in the quest for clinical efficacy , 2006, Nature chemical biology.

[48]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[50]  M. Held,et al.  Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. , 2013, Cancer discovery.